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Impact of a urinary tract infection treatment pathway on antimicrobial
prescribing within a community hospital
Alyssa Donadio, Pharm.D., BCPS; Heidi Clarke, Pharm.D., BCCCP; Erika Dittmar, Pharm.D., BCPS
Baptist Hospital of Miami, Department of Pharmacy; Miami, FL

Background
Treatment algorithms and clinical practice guidelines are
often implemented within healthcare institutions as
measures to reduce healthcare costs while improving
patient outcomes. As antibiotic resistance rates continue to
rise and therapeutic options remain limited, urinary tract
infections (UTIs) represent a growing public health concern.
Based on the institutional formulary, clinical experience,
local resistance patterns, and consensus guidelines, the
P&T Committee at Baptist Health South Florida agreed
upon an evidence-based treatment pathway for UTIs to be
used as guidance for empiric antibiotic treatment. The goal
of this study was to assess whether this pathway is an
effective antibiotic stewardship effort to promote
appropriate antibiotic use.

Phase I
(n=50)

Phase II
(n=50)

Patient characteristics
Average age, years
Gender—female, n (%)
Average baseline WBC count x109/L

76
37 (74%)
10.3

73
0.14
32 (64%) 0.28
11.2
0.30

UTI category
Asymptomatic bacteriuria, n (%)
Acute uncomplicated cystitis, n (%)
Uncomplicated pyelonephritis, n (%)
Severe and/or complicated UTI, n (%)

2 (4)
12 (24)
14 (28)
22 (44)

2 (4)
13 (26)
12 (24)
23 (46)

1.00
0.82
0.65
0.84

ID Consult, n (%)

20 (40)

24 (48)

0.42

Methods
 Bi-phasic, IRB approved study conducted on adult
patients admitted to Baptist Hospital of Miami
 Phase I was a retrospective chart review of 50 randomly
selected patients admitted with a UTI between
November 2016 and October 2017
 Phase II was a prospective review of 50 patients with a
positive urine culture between January 2018 and March
2018, after implementation of the UTI treatment
pathway
 Exclusion criteria:
• Febrile neutropenia
• Acute bacterial prostatitis
• Coexisting infections
 Primary outcome: Percent of patients who received
optimal empiric antibiotic treatment and duration of
therapy before and after implementation of the pathway
 Secondary outcome: length of stay before and after
pathway
 Appropriateness of antibiotic therapy was defined by
the P&T approved treatment algorithm

p value

Phase I
(n=50)

Phase II
(n=50)

p value

Primary Outcome
Optimal antibiotic & duration, n (%)
Optimal empiric antibiotic, n (%)
Optimal antibiotic duration, n (%)

15 (30)
27 (54)
27 (54)

29 (58)
38 (76)
37 (74)

0.005
0.02
0.038

Secondary Outcome
Average length of stay, days

7.8

6.4

0.66

Outcomes

Purpose
To evaluate appropriateness of antibiotic selection and
duration of treatment for urinary tract infections (UTIs)
before and after implementation of a treatment pathway
within Baptist Hospital of Miami.

Results

Demographics

Overall Outcomes
Average duration of therapy, days
Total days of antibiotic therapy
Opportunity for earlier IV to PO conversion, n (%)

8
392
19 (38)

6.7
331
9 (18)

• There were no significant differences in baseline
characteristic between the two groups
• The majority of patients were female and had a
diagnosis of severe and/or complicated UTI
• For the primary outcome of optimal antibiotic selection
and duration of therapy, 15 (30%) of the patients in
phase I prior to pathway implementation were treated
appropriately according to the algorithm, while 29 (58%)
of patients were treated appropriately in phase II after
pathway implementation (p=0.05)
• For the secondary outcome, average length of stay was
reduced from 7.8 days in phase I to 6.7 days in phase II,
although this difference was not found to be statistically
significant (p=0.66)
• Average duration of therapy was reduced from 8 days
during phase I to 6.7 days in phase II, which was
statistically significant (p=0.03)

Conclusion

0.03
0.03

Appropriateness of Antibiotic by UTI Category

Phase I
(n=50)

Phase II
(n=50)

p value

Asymptomatic bacteriuria, n (%)

0/2 (0%)

1/2 (50%)

0.32

Uncomplicated cystitis, n (%)

9/12 (75%) 13/13 (100%) 0.06

Uncomplicated pyelonephritis, n (%)

12/14 (86%) 12/12 (100%) 0.19

Severe and/or complicated UTI, n (%)

6/22 (27%) 12/23 (52%) 0.09

Implementation of a UTI treatment pathway improved
appropriate empiric antimicrobial use, reduced average
length of stay, and reduced average duration of
antimicrobial therapy, thus favoring patient outcomes and
healthcare costs.
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